Burgess MA - Search Results

1

Phase I-II study of piperazinedione in adults with solid tumors and acute leukemia.

Benjamin RS, Keating MJ, Valdivieso M, McCredie KB, Livingston RA, Burgess MA, Rodriguez V, Bodey GP, Gottlieb JA. Benjamin RS, et al. Among authors: burgess ma. Cancer Treat Rep. 1979 Jun;63(6):939-43. Cancer Treat Rep. 1979. PMID: 380802 Clinical Trial.

2

Phase I-II evaluation of cyclocytidine.

Burgess MA, Bodey GP, Minow RA, Gottlieb JA. Burgess MA, et al. Cancer Treat Rep. 1977 May-Jun;61(3):437-43. Cancer Treat Rep. 1977. PMID: 68828

3

Phase I study of maytansine using a 3-day schedule.

Cabanillas F, Rodriguez V, Hall SW, Burgess MA, Bodey GP, Freireich EJ. Cabanillas F, et al. Among authors: burgess ma. Cancer Treat Rep. 1978 Mar;62(3):425-8. Cancer Treat Rep. 1978. PMID: 348310 Clinical Trial.

4

Results of a phase II study of maytansine in patients with breast carcinoma and melanoma.

Cabanillas F, Bodey GP, Burgess MA, Freireich EJ. Cabanillas F, et al. Among authors: burgess ma. Cancer Treat Rep. 1979 Mar;63(3):507-9. Cancer Treat Rep. 1979. PMID: 371803 Clinical Trial.

5

Phase I clinical evaluation of 2,3-dihydro-1H-imidazo[1,2-b]pyrazole.

Yap BS, Murphy WK, Burgess MA, Valdivieso M, Bodey GP. Yap BS, et al. Among authors: burgess ma. Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1849-51. Cancer Treat Rep. 1979. PMID: 526919

6

Phase I study of L-alanosine using a daily x 3 schedule.

Dosik GM, Stewart D, Valdivieso M, Burgess MA, Bodey GP. Dosik GM, et al. Among authors: burgess ma. Cancer Treat Rep. 1982 Jan;66(1):73-6. Cancer Treat Rep. 1982. PMID: 7053269

7

Doxorubicin-DNA complex: a phase I clinical trial.

Hall SW, Benjamin RS, Burgess MA, Bodey GP, Luna MA, Freireich EJ. Hall SW, et al. Among authors: burgess ma. Cancer Treat Rep. 1982 Dec;66(12):2033-7. Cancer Treat Rep. 1982. PMID: 7139645

8

Phase I study of 3-deazauridine in the treatment of adults with solid tumors.

Stewart DJ, McCredie KD, Barlogie B, Valdivieso M, Benjamin RS, Burgess MA, Bodey GP. Stewart DJ, et al. Among authors: burgess ma. Cancer Treat Rep. 1980;64(12):1295-9. Cancer Treat Rep. 1980. PMID: 7471119

9

Phase I clinical study of dihydroxyanthracenedione administered on a 5-day iv schedule.

Valdivieso M, Bedikian AY, Burgess MA, Savaraj N, Jeffers WB, Bodey GP. Valdivieso M, et al. Among authors: burgess ma. Cancer Treat Rep. 1981 Sep-Oct;65(9-10):841-4. Cancer Treat Rep. 1981. PMID: 7273017

10

COMB (cyclophosphamide, oncovin, methyl-CCNU, and bleomycin): a four-drug combination in solid tumors.

Livingston RB, Einhorn LH, Bodey GP, Burgess MA, Freireich EJ, Gottlieb JA. Livingston RB, et al. Among authors: burgess ma. Cancer. 1975 Aug;36(2):327-32. doi: 10.1002/1097-0142(197508)36:2<327::aid-cncr2820360206>3.0.co;2-u. Cancer. 1975. PMID: 50870

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

240 results

Search Page